This PBPK/PD model provides a robust framework for precision clozapine therapy, supporting genotype-guided dosing and TDM to optimize efficacy and safety. The implementation of pharmacogenetic testing could transform clinical practice, offering a framework for optimized resource utilization and risk minimization.
Mishra et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: